.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Accenture
Mallinckrodt
Harvard Business School
Citi
Fuji
Merck
McKesson
Fish and Richardson
Chinese Patent Office

Generated: September 25, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
Abstract:There is disclosed a method for treating a patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amount of ribavirin and a therapeutically effective amount of interferon-alpha for a time period of from 20 up to 80 weeks.
Inventor(s): Albrecht; Janice K. (Winter Park, FL)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:08/938,033
Patent Claims: 1. A method of treating a patient having chronic hepatitis C infection having HCV genotype 1 and having a viral load of greater than 2 million copies/mL of serum HCV-RNA as measured by HCV-RNA/qPCR to eradicate detectable HCV-RNA comprising administering a therapeutically effective combination of ribavirin and interferon-alpha for a time period of at least 24 weeks wherein the patient has fewer than about 100 copies/mL of serum HCV-RNA at the end of said period and also has less than about 100 copies/mL of serum HCV-RNA for at least 24 weeks after the end of said period.

2. The method of claim 1, wherein the amount of ribavirin administered is from about 400 to about 1200 mg per day.

3. The method of claim 1, wherein the amount of ribavirin administered is from about 800 to about 1200 mg per day.

4. The method of claim 1, wherein the interferon-alpha administered is selected from interferon alpha-2a, interferon alpha-2b, a consensus interferon, a purified interferon alpha product or a pegylated interferon-alpha.

5. The method of claim 2, wherein the amount of the interferon-alpha administered is selected from interferon alpha-2a, interferon alpha-2b or a purified interferon alpha product and the amount of the interferon-alpha administered is from about 2 to about 10 million IU per week on a weekly, TIW, QOD or daily basis.

6. The method of claim 3, wherein the amount of the interferon-alpha administered is about 3 million IU TIW.

7. The method of claim 2, wherein the interferon-alpha administered is interferon alpha-2b and the amount of the interferon-alpha administered is about 3 million IU TIW.

8. The method of claim 2, wherein the interferon-alpha administered is consensus interferon and the amount of the interferon-alpha administered is from about 1 to about 20 micrograms per week on a weekly, TIW, QOD or daily basis.

9. The method of claim 2, wherein the interferon-alpha administered is pegylated interferon alpha-2b and the amount of the interferon-alpha administered is from about 0.5 to about 2.0 micrograms/kilogram per week on a weekly, TIW, QOD or daily basis.

10. The method of claim 2,wherein the interferon-alpha administered is pegylated interferon alpha-2a and the amount of the interferon-alpha administered is from about 20 to about 250 micrograms/kilogram per week on a weekly, TIW, QOD or daily basis.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
QuintilesIMS
Fish and Richardson
Chinese Patent Office
Chubb
US Army
Deloitte
AstraZeneca
Novartis
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot